Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.

NCT05987956 is registered in ClinicalTrials.gov with Medicine Invention Design, Inc as lead sponsor.

NCT NCT05987956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
Lead sponsor
Medicine Invention Design, Inc
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 18, 2026
Completion date
December 28, 2026
Enrollment
600 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non-small cell lung cancer (nsclc)